Oncolytics Biotech Inc. (ONCY) DCF Valuation

Oncolytics Biotech Inc. (ONCY) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Oncolytics Biotech Inc. (ONCY) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Whether you're an investor or analyst, this (ONCY) DCF Calculator is your go-to resource for accurate valuation. Preloaded with real data from Oncolytics Biotech Inc., you can adjust forecasts and observe the effects instantly.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -13.9 -17.6 -17.8 -18.6 -23.4 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .3 .3 .3 .3 .1 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -14.2 -17.9 -18.1 -18.9 -23.5 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 9.8 21.7 28.6 22.3 24.2 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .1 .0 .4 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable .0 .0 .4 1.6 .8 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 .0 -.2 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % -0.35075 -0.35075 -0.35075 -0.35075 -0.35075 -0.35075 -0.35075 -0.35075 -0.35075 -0.35075
EBITAT -19.6 -15.6 -18.2 -19.0 -23.5 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -19.2 -15.3 -17.6 -17.9 -23.9 -.7 .0 .0 .0 .0
WACC, % 11.53 11.52 11.53 11.53 11.53 11.53 11.53 11.53 11.53 11.53
PV UFCF
SUM PV UFCF -.7
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -1
Net Debt -24
Equity Value 23
Diluted Shares Outstanding, MM 68
Equity Value Per Share 0.34

What You Will Receive

  • Pre-Filled Financial Model: Oncolytics Biotech Inc.’s actual data allows for accurate DCF valuation.
  • Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other critical factors.
  • Real-Time Calculations: Automatic updates provide immediate feedback as you make adjustments.
  • Investor-Ready Template: A polished Excel file crafted for high-quality valuation presentations.
  • Customizable and Reusable: Designed for adaptability, enabling repeated use for in-depth forecasts.

Key Features

  • Comprehensive DCF Analysis: Offers detailed unlevered and levered DCF valuation models tailored for Oncolytics Biotech Inc. (ONCY).
  • WACC Calculation Tool: Pre-configured Weighted Average Cost of Capital sheet with adjustable parameters.
  • Customizable Forecast Inputs: Easily alter growth projections, capital expenditures, and discount rates.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for Oncolytics Biotech Inc. (ONCY).
  • Interactive Dashboard and Visuals: Graphical representations that encapsulate essential valuation metrics for straightforward analysis.

How It Works

  • 1. Open the Template: Download and open the Excel file containing Oncolytics Biotech Inc.'s (ONCY) preloaded data.
  • 2. Edit Assumptions: Modify key inputs such as growth rates, WACC, and capital expenditures.
  • 3. View Results Instantly: The DCF model automatically calculates intrinsic value and NPV based on your inputs.
  • 4. Test Scenarios: Analyze various forecasts to evaluate different valuation outcomes.
  • 5. Use with Confidence: Deliver professional valuation insights to enhance your decision-making process.

Why Choose Oncolytics Biotech Inc. (ONCY)?

  • Innovative Treatments: Pioneering therapies that target cancer with precision.
  • Strong Research Foundation: Backed by robust clinical trials and scientific validation.
  • Experienced Leadership: Guided by a team of industry veterans with a proven track record.
  • Commitment to Patients: Focused on improving patient outcomes and quality of life.
  • Growing Pipeline: A diverse range of products in development to address unmet medical needs.

Who Should Use This Product?

  • Investors: Accurately assess Oncolytics Biotech Inc.'s (ONCY) fair value before making investment choices.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Oncolytics Biotech Inc. (ONCY).
  • Consultants: Efficiently customize the template for valuation reports tailored to clients interested in Oncolytics Biotech Inc. (ONCY).
  • Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
  • Educators: Implement it as a teaching resource to illustrate valuation methodologies in the biotech sector.

What the Template Contains

  • Pre-Filled Data: Contains Oncolytics Biotech Inc.'s historical financials and projections.
  • Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
  • Key Financial Ratios: Assess Oncolytics Biotech Inc.'s profitability, efficiency, and leverage.
  • Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
  • Clear Dashboard: Visuals and tables summarizing key valuation outcomes.

Es wurden keine passenden Produkte gefunden.